Proteinase 3 and prognosis of patients with acute myocardial infarction by Ng, Leong L. et al.
Clinical Science (2011) 120, 231–238 (Printed in Great Britain) doi:10.1042/CS20100366 231
Proteinase 3 and prognosis of patients with
acute myocardial infarction
Leong L. NG, Sohail Q. KHAN, Haﬁd NARAYAN, Paulene QUINN, Iain B. SQUIRE
a n dJ o a nE .D A V I E S
Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Inﬁrmary,
Leicester LE2 7LX, U.K., and Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenﬁeld Hospital,
Leicester LE3 9QP, U.K.
ABSTRACT
A multimarker approach may be useful for risk stratiﬁcation in AMI (acute myocardial infarction)
patients, particularly utilizing pathways that are pathophysiologically distinct. Our aim was to assess
the prognostic value of PR3 (proteinase 3) in patients post-AMI. We compared the prognostic
value of PR3, an inﬂammatory marker, with an established marker NT-proBNP (N-terminal pro-
B-type natriuretic peptide) post-AMI. We recruited 900 consecutive post-AMI patients (700 men;
age, 64.6+ −12.4 years) in a prospective study with follow-up over 347 (0–764) days. Plasma PR3
was signiﬁcantly higher in patients who died [666.2 (226.8–4035.5) ng/ml; P<0.001] or were
readmitted with heart failure [598 (231.6–1803.9) ng/ml, P<0.004] compared with event-free
survivors [486.9 (29.3–3118.2) ng/ml]. Using Cox modelling, log10 PR3 [HR (hazard ratio), 3.80]
and log10 NT-proBNP (HR, 2.51) were signiﬁcant independent predictors of death or heart
failure. When patients were stratiﬁed by plasma NT-proBNP (median, 1023 pmol/l), PR3 gave
additional predictive value for death or heart failure, in both the patients in whom NT-proBNP
level was above the median (log rank for trend, 12.54; P<0.0004) and those with NT-proBNP level
below the median (log rank for trend, 3.83; P<0.05). Neither marker predicted recurrent AMI.
In conclusion, this is the ﬁrst report showing a potential role for the serine protease PR3 in
determining mortality and incidence of heart failure following AMI, independent of established
conventional risk factors. PR3 may represent a clinically useful marker of prognosis after an AMI
as part of a multimarker strategy.
INTRODUCTION
Atherosclerosis is associated with inﬂammatory changes
in the blood vessel wall [1], including macrophage and
lymphocyte inﬁltration. There is an association between
neutrophil count and the risk of future acute coronary
syndromes [2], and recent evidence has documented
elevated neutrophil activity in acute coronary syndromes
[3,4].Despitetheirroleinplaquedestabilizationandacute
coronary syndromes, it is not known whether neutrophil
activation, with degranulation of their proteolytic
enzymes might play a role in development of chronic
heart failure and the risk of mortality following an AMI
(acute myocardial infarction).
MPO (myeloperoxidase), an enzyme present within
the azurophilic granules of neutrophils, may stimulate
plaquedestabilizationbyactivationofmetalloproteinases
[5]. Plasma levels of MPO are raised in coronary
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artery disease [6] and predict outcome of patients
presenting with chest pain [7] and acute coronary
syndromes [8,9]. PR3 (proteinase 3) is another major
component of neutrophil azurophilic granules, together
with other serine proteases such as elastase and cathepsin
G [10]. Azurophilic granules are released in response
to powerful stimuli to neutrophils, whereas secretory
granules (which also contain PR3 [11]) are released
with weaker stimuli. PR3 may also be expressed on
endothelial cells [12]. Neutrophil serine proteases may
degrade extracellular matrix; in addition, PR3 has other
deleterious effects which may be relevant to a role in
pathogenesis of vasculitis in Wegener’s granulomatosis
and potentially in prognosis of patients post-AMI. These
include induction of apoptosis through a caspase-like
activity on endothelial cells [13], releasing activated
TNFα (tumour necrosis factor α) from its nascent
membrane-bound precursor form [14,15], activation of
the pro-inﬂammatory mediators IL (interleukin)-1β [15]
andIL-18[16]andgenerationofangiotensinIandIIfrom
angiotensinogen [17]. Although PR3 and autoantibodies
to it [ANCA (antineutrophil cytoplasmic antibodies)]
are prime candidates for pathogenesis of vasculitis and
tissue damage in the relatively uncommon autoimmune
conditionofWegener’sgranulomatosis,theassociationof
PR3 with morbidity and mortality in common medical
vascular presentations such as AMI has never been
examined.
PR3 is rapidly inactivated by irreversible binding to
SERPIN A1 (α1-antitrypsin) [18,19], where the serine
proteasereacts with the reactive centre loop ofthe serpin,
generating a covalently bound intermediate resulting in
the distortion and inactivation of the protease [20]. Thus
little free PR3 exists in plasma, and it is mainly present as
a PR3–SERPIN A1 complex [18].
We hypothesized that measurement of such PR3–
SERPIN A1 complexes would provide prognostic
information on heart failure and mortality post-AMI,
even when used in conjunction with recognized markers
of prognosis such as BNP (B-type natriuretic peptide)
or its precursor NT-proBNP (N-terminal pro-BNP)
in order to establish a role for neutrophil activation in
determining these adverse outcomes. Since PR3 is
easily mobilized from secretory granules compared with
azurophilic granules, it may also be a better marker of
neutrophil activation than MPO.
MATERIALS AND METHODS
Study population
We recruited 900 consecutive patients with acute
myocardial infarction admitted to the Coronary Care
Unit of Leicester Royal Inﬁrmary between 1 September
2003 and 31 July 2007. Written informed consent was
obtained from patients, and the study complied with the
Declaration of Helsinki and was approved by the local
ethics committee. AMI was diagnosed if a patient had a
plasma creatine kinase-MB elevation greater than twice
normal or cardiac troponin I level >0.1 ng/ml with at
least one of the following, chest pain lasting >20 min
or diagnostic serial ECG changes consisting of new
pathologicalQwavesorSTsegmentandTwavechanges.
Exclusion criteria included malignancy or recent surgery
(within 1 month). Hypertension was deﬁned as a blood
pressure measurement of greater than 140/90 mmHg on
twoormoreoccasionsorifthepatientwasonmedication
for hypertension. Hypercholesterolaemia was deﬁned
as a total cholesterol of greater than 5.0 mmol/l,
or treatment with a statin. Diabetes was deﬁned as a
random plasma glucose of 11.1 mmol/l, fasting plasma
glucose of 7 mmol/l or a history of diabetes on treatment.
Plasma samples
Blood samples were drawn at 2–5 days after the onset of
chest pain for determination of plasma PR3–SERPIN A1
and NT-proBNP. After 15 min bed rest, 20 ml of blood
was collected into tubes containing EDTA and aprotinin.
All plasma was stored at −80◦C until assayed, blind to
clinical details, in a single batch.
Echocardiography
Transthoracic echocardiography was performed in
patients using a Sonos 5500 instrument (Philips Medical
Systems), at 3–5 days post-admission. A 16-segment
LVWMI (left ventricular wall motion index) based on
the American Society of Echocardiography mode was
derived by scoring each LV segment [1 = normal, 2 =
hypokinesis,3=akinesisand4=dyskinesis(paradoxical
motion)] and dividing the total by the number of
segments scored. LVEF (left ventricular ejection fraction)
was calculated using the biplane method of discs formula
[21]. Impaired LV systolic function was deﬁned as an
LVEF <40% or a LVWMI >1.8.
NT-proBNP assay
Plasma NT-proBNP assay was measured using a non-
competitive immunoluminometric assay as previously
published [22]. Samples or NT-proBNP standards
(10 μl) were incubated in ELISA plate wells coated
with mouse monoclonal IgG directed to the C-
terminalofNT-proBNP.Detectionwaswithbiotinylated
rabbit N-terminal antibody followed by MAE (methyl-
acridinium ester)-labelled streptavidin on an MLX plate
luminometer (Dynex Technologies). The lower limit of
detectionwas0.3 pmol/l.Thishighlyspeciﬁcassayshows
no cross-reactivity with ANP (atrial natriuretic peptide),
BNP or CNP (C-type natriuretic peptide).
PR3–SERPIN A1 assay
Plasma PR3–SERPIN A1 was measured using a non-
competitive immunoluminometric assay modiﬁed from
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a method published previously [18]. ELISA plate wells
were coated with 200 ng of mouse monoclonal antibody
to PR3 (clone 1B10, IgG2a; HyTest). Standards were
produced by incubating PR3 with a 20-fold molar excess
of SERPIN A1 (both from Sigma–Aldrich). Samples
or standards (10 μl) were incubated with assay buffer
(100 μl) in the coated wells for 24 h at 4◦C. Following
washes, a speciﬁc SERPIN A1 rabbit antibody (Dako)
was pipetted into the wells (20 ng/100 μl) and incubated
for 3 h with shaking at 250 Hz at room temperature
(22◦C). Following washing, a goat biotinylated anti-
rabbit IgG (Rockland Immunochemicals), previously
preadsorbed with human, rabbit and mouse serum
proteins, at a dilution of 1:100000 was incubated within
the wells for 1 h, followed by MAE-labelled streptavidin
for another 1.5 h. Chemiluminescence was elicited with
sequential injections of H2O2 in nitric acid, followed by
NaOH containing cetyl trimethylammonium bromide,
as described previously [22]. Intra- and inter-assay
coefﬁcients of variation were found to be less than 10%.
MPO assay
TheMPOassaywasbasedonatwo-sitenon-competitive
immunoluminometric assay which employed an ELISA
plate immobilized monoclonal MPO antibody (100 ng/
100 μl; Research Diagnostics) and a rabbit polyclonal
antibody(50 ng/100μl; MerckBioSciences), as described
previously [23]. Standards and 10 μl of plasma were
incubated in plates overnight, before washing and dete-
ction using goat biotinylated anti-rabbit IgG and
streptavidin–MAE, as described for the PR3–SERPIN
A1 assay. The MPO assays had inter- and intra-assay
coefﬁcients of variation <10%, with a lower limit of
detection of 0.3 ng/ml.
End points
The primary end point was the combination of all-
cause mortality and hospitalization for heart failure.
Secondary end points included the occurrence of further
myocardial infarction. Hospitalization for heart failure
was deﬁned as a hospital admission for which heart
failure was the primary reason, requiring treatment with
high-dose diuretics, inotropes or intravenous nitrate.
Deaths were validated by reviewing the hospital record
managementsystemsandtheOfﬁceofNationalStatistics
Registry. Heart failure episodes were identiﬁed through
the hospital record management systems and validated
by contacting each patient. There was a minimum 60-day
follow-up of all surviving patients.
Statistical analysis
Values are medians (range), unless otherwise stated.
Statistical analyses were performed on SPSS Version 14.0.
Continuous variables were compared using the Mann–
WhitneyU test.ANOVAwiththeBonferronicorrection
for multiple comparisons was employed when more
than two groups were compared. Correlation analysis
employed Spearman’s rho, and binary logistic regression
and Cox proportional hazard analyses were used to
developmodelsinordertotesttheindependentpredictive
power for factors and variables. Plasma levels of NT-
proBNP, MPO and PR3–SERPIN A1 were normalized
by log-transformation. Thus ORs (odds ratios) and
HRs (hazard ratios) refer to a 10-fold rise in the levels
of these markers. Kaplan–Meier survival analysis was
used to assess dichotomized values of NT-proBNP
and PR3–SERPIN A1 and the log rank test was used
for comparison of groups. ROC (receiver-operating
characteristic) curves were generated and the AUC (area
under the curve) was calculated to assess the accuracy of
predictors [24]. A P value of less than 0.05 was deemed to
be statistically signiﬁcant.
RESULTS
Patient characteristics
The demographic features of the patient population are
shown in Table 1. Median length of follow-up was
347 days with a range of 0–764 days. No patient was lost
to follow-up. The index AMI was classed as STEMI (ST
elevationMI)in777ofthepatients,529(68.1%)ofwhom
received thrombolytic therapy. Echocardiographic data
were available for 622 (69.1%) of the patients during the
indexadmission.Duringfollow-up,92(10.2%)ofthe900
patients died, 66 (7.3%) experienced readmission with
heart failure, 143 (15.9%) patients experienced either end
point and 62 (6.9%) experienced hospitalization with
recurrent AMI.
Plasma PR3–SERPIN A1, NT-proBNP and
MPO levels
Plasma levels of PR3–SERPIN A1 in patients with
AMI ranged from 29.3 to 4035.5 ng/ml, with a median
of 504.6 ng/ml, and were elevated compared with the
established normal range [350 (110–580) ng/ml]. PR3–
SERPINA1wassigniﬁcantlyhigherinpatientswhodied
[666.2(226.8–4035.5)ng/ml;P<0.001usingBonferroni’s
correction] or were readmitted with heart failure [598
(231.6–1803.9) ng/ml; P<0.004] compared with event-
free survivors [486.9 (29.3–3118.2) ng/ml]. In contrast,
levels of PR3–SERPIN A1 in those readmitted with
recurrent AMI [482.5 (168.9–1753.9) ng/ml] were similar
to those in event-free survivors. PR3–SERPIN A1 levels
were similar in males and females, and in those with or
without previous histories of hypertension, angina, AMI
or heart failure, but were slightly elevated in those with
diabetes[547.0(76.9–4035.5) ng/ml]comparedwithnon-
diabetic patients [495.1 (29.3–3118.2) ng/ml; P<0.018].
Plasma PR3–SERPIN A1 levels were modestly
correlated with plasma glucose (rs = 0.08, P<0.03),
log creatinine (rs = 0.13, P<0.001), Killip class (rs=
0.10, P<0.002), NT-proBNP (rs = 0.25, P<0.001)
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Table 1 Characteristics of patients in the study
Values are means (S.D.) or numbers (%). ACE, angiotensin-converting enzyme; CK,
creatine kinase.
Charactertisitc AMI patients
Number (n) (male) 900 (700)
Age (years) 64.6+ −12.4
Previous medical history (n)
Myocardial infarction 165 (18.3%)
Angina pectoris 195 (21.7%)
Hypertension 391 (43.4%)
Diabetes mellitus 192 (21.3%)
Hypercholesterolaemia 221 (24.6%)
Current/ex-smokers 560 (62.2%)
ST elevation AMI 777 (86.3%)
Thrombolytic 529 (58.8%)
Territory of infarct (n)
Anterior 369 (41.0%)
Inferior 373 (41.4%)
Other/undetermined 158 (17.6%)
Killip class on admission (n)
I 457 (50.7%)
II 357 (39.7%)
III 77 (8.6%)
IV 9 (1.0%)
Peak CK (units/l) 1157+ −1263
Creatinine (μmol/l) 103.9+ −35.4
Medication (n)
Aspirin 794 (88.2%)
ACE inhibitors/angiotensin receptor blockers 683 (75.9%)
β-Blockers 721 (80.1%)
Statins 701 (77.9%)
and creatine kinase (rs = 0.13, P<0.001) but had
no relationship to age, site of infarction, presence or
absence of ST elevation and whether thrombolysis was
administered or not.
In conﬁrmation of previous work, plasma NT-
proBNP was higher in patients who died [5955.4 (9.02–
14057.2) pmol/l] or were readmitted with heart failure
[3106.6 (2.4–12282.9) pmol/l] compared with event-free
survivors [806.8 (0.3–28886) pmol/l; P<0.001 for both].
NT-proBNP levels were higher in females [1951.7 (22.9–
15732) pmol/l] compared with males [871.6 (0.3–28886)
pmol/ml; P<0.001) and correlated with age (rs = 0.46,
P<0.001), plasma glucose (rs = 0.15, P<0.001), log
creatinine (rs = 0.27, P<0.001), Killip class (rs = 0.29,
P<0.001) and creatine kinase (rs = 0.13, P<0.001).
Plasma MPO was signiﬁcantly higher in patients
who died [36.7 (6.44–132.1) ng/ml; P<0.035 using
Bonferroni’s correction] compared with event-free
survivors [24.6 (0.3–405.2) ng/ml]. In contrast those
who were readmitted with heart failure [27.6 (6.5–210.8)
ng/ml] or with recurrent AMI [23.9 (5.3–189.9) ng/ml]
Table 2 Binary logistic regression model for the prediction
of death and heart failure
Variable Odds ratio 95% CI P value
Age 1.04 1.02–1.07 0.001
Gender 0.57 0.35–0.93 0.024
Past history AMI 2.28 1.43–3.74 0.001
Killip class >1 1.66 1.05–2.63 0.032
Log creatinine 18.55 3.02–113.9 0.001
Log NT-proBNP 2.79 1.79–4.37 0.001
Log PR3–SERPIN A1 6.42 2.25–18.3 0.001
had similar values of MPO to event-free survivors. MPO
levels were higher in females [30.3 (0.3–405.2) ng/ml]
compared with males [23.9 (3.6–215.1) ng/ml; P<0.001]
and in patients with diabetes [30.4 (5.1–238.7) ng/ml]
compared with non-diabetic patients [24.0 (0.3–405.2)
ng/ml; P<0.001] and were correlated with age (rs =
0.12, P<0.001), plasma glucose (rs = 0.10 P<0.009), log
creatinine(rs =0.11,P<0.001)andKillipclass(rs =0.11,
P<0.002).
There was a modest correlation of plasma PR3–
SERPIN A1 with impaired LV systolic function (rs =
0.16, P=0.001) on the index admission (as deﬁned by
LVEF<40% or LVWMI>1.8 on echocardiography),
with a stronger relationship demonstrated for NT-
proBNP (rs = 0.35, P=0.001). Plasma MPO was weakly
correlated to PR3–SERPIN A1 and NT-proBNP (rs =
0.11 and 0.12, respectively, P=0.002) but not to LV
systolic function.
Primary end points: PR3–SERPIN A1 and
NT-proBNP as predictors of death or
heart failure
Binary logistic models were developed for prediction
of death or heart failure, using the following clinical
and demographic variables: age, gender, past history
of AMI, hypertension or diabetes, Killip class >1,
thrombolytic use, log creatinine, NT-proBNP, MPO and
PR3–SERPIN A1. Independent predictors are reported
in Table 2 and include NT-proBNP and PR3–SERPIN
A1 as signiﬁcant predictor variables. The Nagelkerke r2
was 0.35 suggesting a good ﬁt of the model.
The ROC curve for the predictive value of PR3–
SERPINA1fortheprimaryendpointyieldedanAUCof
0.65[95%CI(conﬁdenceinterval),0.60–0.70;P<0.001);
for NT-proBNP, the AUC was 0.78 (95% CI, 0.74–0.83;
P<0.001).Thelogisticmodelcombiningthetwomarkers
yielded an AUC of 0.84 (95% CI, 0.80–0.88; P<0.001),
which exceeded that of either peptide alone (P<0.003 by
method of Hanley and McNeil [24]).
Cox proportional hazards modelling conﬁrmed these
ﬁndings, identifying the same independent predictors of
death or heart failure apart from gender (Table 3). In
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Table 3 Multivariate Cox proportional hazards regression
model of the signiﬁcant predictors of death or heart failure
Variable HR 95% CI P value
Age 1.04 1.03–1.06 0.001
Past history AMI 1.52 1.06–2.17 0.023
Killip class >1 1.60 1.08–2.37 0.02
Log creatinine 4.75 1.39–16.19 0.013
Log NT-proBNP 2.51 1.70–3.71 0.001
Log PR3–SERPIN A1 3.80 1.78–8.14 0.001
Figure 1 Cumulative incidence plots showing time to
adverse events (death or heart failure) in patients stratiﬁed
by PR3–SERPIN A1
both logistic and Cox models, plasma MPO was not an
independent predictor of death or heart failure.
Kaplan–Meier survival analysis demonstrated a
signiﬁcantlybetterclinicaloutcomeinpatientswithPR3–
SERPIN A1 below the median (504.6 ng/ml) compared
with those with PR3–SERPIN A1 above the median
(log rank, 28.15; P<0.0001) (Figure 1). The event-free
survivalcurvesdivergeearlyandcontinuetodivergeeven
after 2 years. This was also true for NT-proBNP (log
rank, 64.72; P<0.0001). When patients were stratiﬁed
by plasma NT-proBNP (median 1023 pmol/l), PR3–
SERPIN A1 gave additional predictive value for death or
heart failure, in both the patients in whom NT-proBNP
level was above the median (log rank for trend, 12.54;
P<0.0004) and those with NT-proBNP level below
the median (log rank for trend, 3.83; P<0.05). Those
patientswithbothmarkerselevatedabovetheirrespective
medians had higher event rates than those with either
marker elevated above the median, and these in turn had
higher event rates than those with both markers below
their respective medians (P<0.001 for all comparisons)
(Figure 2).
Figure 2 Cumulative incidence plots showing time to
adverse events (death or heart failure) in patients stratiﬁed
according to whether both PR3–SERPIN A1 and NT-proBNP
are below their respective median values, either marker
being elevated or both markers elevated above median
Troponin levels were available for 414 patients.
InclusionoftroponinintheCoxmodelfordeathorheart
failure led to the following HRs (and P values): age (1.07,
P<0.001), Killip class >1 (1.83, P<0.04), log creatinine
(6.05,P<0.06),pasthistoryofAMI(1.70,P<0.07),NT-
proBNP (1.74, P<0.08), troponin (1.18, P=0.3), PR3–
SERPIN A1 (2.83, P<0.06).
Echocardiography scans were analysable on 622
subjects, of which 203 showed evidence of LV systolic
dysfunction (as deﬁned by LVEF <40% or LVWMI
>1.8).Inclusionofechocardiographyevidenceofsystolic
dysfunction into the Cox model for death or heart failure
led to the following HRs (and P values): age (1.04,
P<0.001),Killipclass>1(2.17,P<0.005),logcreatinine
(6.55,P<0.01),pasthistoryofAMI(1.40,P=0.13),NT-
proBNP (1.92, P<0.007), LV systolic dysfunction (1.39,
P=0.13) and PR3–SERPIN A1 (2.88, P<0.02).
Reclassiﬁcation analyses for predictors of
death or heart failure
The GRACE score [25] is a recognized risk predictor
in AMI, enabling patients to be classiﬁed into low,
intermediate and high risk groups for major adverse
cardiac events after an acute coronary syndrome, and
incorporates many of the above predictors for death or
heart failure, e.g. age, history of AMI, elevated plasma
creatinine, elevated biomarker levels, Killip class. In this
present study, GRACE score was a signiﬁcant predictor
of death or heart failure [HR, 1.03 (95% CI, 1.02–
1.04; P<0.0005]. In a model for predicting death or
heart failure using GRACE score, NT-proBNP and
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Table 4 Reclassiﬁcation analysis for death or heart failure using the GRACE score, with the addition of NTproBNP and/or
PR3–SERPIN A1
(a) GRACE score compared with GRACE score with NT-proBNP
Reclassiﬁcation
Parameter Increased Decreased Correctly reclassiﬁed P value
Patients without end points 8.9% 16.3% 7.4% 0.0002
Patients with end points 15.3% 7.0% 8.3%
(b) GRACE score compared with GRACE score with PR3–SERPIN A1
Reclassiﬁcation
Parameter Increased Decreased Correctly reclassiﬁed P value
Patients without end points 10.3% 11.4% 1.1% 0.02
Patients with end points 9.1% 2.3% 6.8%
(c) GRACE score with NT-proBNP compared with GRACE score with NT-proBNP and PR3–SERPIN A1
Reclassiﬁcation
Parameter Increased Decreased Correctly reclassiﬁed P value
Patients without end points 8.6% 7.9% −0.7% 0.14
Patients with end points 7.6% 2.3% 5.3%
PR3–SERPIN A1, all three remained signiﬁcant pre-
dictors [HR (95% CI) were 1.02 (1.01–1.03); P<0.0005
for the GRACE score; 2.67 (1.79–3.99); P<0.0005 for
NT-proBNP; and 4.08 (1.89–8.79); P<0.0005 for PR3–
SERPIN A1].
Reclassiﬁcation analyses were therefore performed
using GRACE score, with the addition of NT-proBNP
and PR3–SERPIN A1 as described by Pencina et al.
[26]. NT-proBNP led to signiﬁcant up-classiﬁcation of
patientswithendpointsanddown-classiﬁcationofevent-
free survivors (Table 4), when added to the GRACE
score (P<0.0002). PR3–SERPIN A1 in addition to the
GRACE score also led to signiﬁcant (P<0.02) up-
classiﬁcation of patients with end points, although when
added to GRACE score with NT-proBNP, this up-
classiﬁcation was not signiﬁcant (P=0.14).
Secondary end points: PR3–SERPIN A1
and NT-proBNP as predictors of
myocardial infarction
Compared with survivors with no end points, patients
whowerereadmittedwithfurtherAMIduringfollow-up
had similar NT-proBNP [1480.7 (2.6–10645.9) compared
with 806.8 (0.3–28886) pmol/l), PR3–SERPIN A1 levels
[482.5 (168.9–1753.9) compared with 486.9 (29.3–3118.2)
ng/ml) and MPO levels [23.9 (5.3–189.9) compared with
24.6 (0.3–405.2) ng/ml].
DISCUSSION
This study reports, for the ﬁrst time, the prognostic
potential of PR3–SERPIN A1 in a large cohort of
patients with AMI, recruited prospectively from a
single centre. This complex of a serine protease and
its inhibitor provided prediction of death or heart
failure, independently of established conventional risk
factors such as renal function and clinical demographic
information and the GRACE score. Moreover, this
novel prognostic marker complements the information
provided by an established marker of poor prognosis
post-AMI, namely NT-proBNP. The use of PR3–
SERPIN A1 for independent prediction of death or
heart failure, together with troponin levels or echocar-
diographic evidence of systolic dysfunction, failed to
achieve conventional levels of statistical signiﬁcance due
to the reduced number of subjects with data available for
analysis.ReclassiﬁcationanalyseswiththeGRACEscore
suggested that PR3–SERPIN A1 had utility, mainly in
up-classifying patients with end points, in contrast with
NT-proBNP, which up-classiﬁed those with end points
and down-classiﬁed those without end points. However,
adding PR3–SERPIN A1 to models with GRACE score
and NT-proBNP led to insigniﬁcant up-classiﬁcation
of patients with end points. The study may have been
underpowered to detect signiﬁcant reclassiﬁcation in this
analysis.
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ThemeasurementofPR3levelsinthepostAMIsetting
is supported by strong evidence of its damaging role
in cells, such as its proapoptotic activity [13] and its
proinﬂammatory effect, by releasing the active forms of
both TNFα, IL-1β, IL-18 [14–16] and the angiotensins
[17]. These cytokines may be especially relevant to
developmentofheartfailurepost-AMI,whichstilloccurs
despite therapy with inhibitors of the renin–angiotensin
system. The involvement of such serine proteases in
the development of heart failure and their association
with increased risk of adverse outcome post-AMI may
supportthesearchfornewagentsthatcouldattenuatethe
damaging effects of these enzymes. For example, there is
preliminary evidence that elaﬁn, a serine protease inhib-
itor could reduce the vascular and myocardial damage in
experimental models of cardiac transplantation [27].
The source of circulating PR3 may be partly from
degranulating, activated neutrophils, being present in
both azurophilic and secretory granules. Neutrophils
are known to inﬁltrate myocardium after infarction,
although their direct contribution to the development of
heartfailuretomortalityafterAMIhasnotbeenclariﬁed.
Alternatively, or additionally, PR3 may be secreted from
endothelialcells[12]orfromlungparenchymalcells[28].
Pneumocytes in normal lung have been demonstrated
to express PR3 [28], although expression is greatly up-
regulated in Wegener’s granulomatosis. Active PR3 is
rapidly inactivated in the plasma by SERPIN A1 and
alpha2-macroglobulin [10], the PR3-SERPIN A1 com-
plex can therefore only be formed with an active protease
and may therefore be a good measure of the amount of
active enzyme that has been secreted. However, these
plasma-borne inhibitors may not have rapid access to
extravascular sites where the enzyme could be released
post-AMI. The levels of the PR3–SERPIN A1 complex
that we have demonstrated in patients who have a poor
outcome post-AMI are very similar to those described
in patients with active vasculitis in Wegener’s granulo-
matosis [560 (110–3940) ng/ml] [29]. In normal subjects
and those with inactive vasculitis, levels of approx. 350
(110–580)ng/mlhavebeenreported[29],whicharelower
than our values for our event-free post-AMI survivors.
In this cohort of AMI patients, MPO did not provide
independent prediction of death or heart failure, when
models included NT-proBNP and PR3-SERPIN A1.
MPO is localized within neutrophil azurophilic granules
alone, which are released with strong stimuli [10], in
contrast to the presence of an easily mobilizable pool
of PR3 in secretory granules [11]. In addition, previous
studies with MPO have included patients with acute
coronary syndromes or chest pain [7,8], which may be
a different spectrum from those with more myocardial
damage. Indeed, Baldus et al. [8] reported prognostic
potential of MPO in those with low or medium troponin
T elevations, with poorer predictive potential in those
with high troponin T levels.
Survival analysis revealed that those at highest risk
were those with NT-proBNP elevated above the median
of 1023 pmol/l and PR3–SERPIN A1 above the
median of 504.6 ng/ml. It is uncertain whether intensi-
ﬁcation of therapy or provision of timely intervention
procedures could have altered clinical outcome, but this
remains to be investigated.
Limitations of the study
This was a single centre study, and the results need to
be replicated in larger multicentre studies. There was a
preponderance of ST elevation AMI, and the utility of
PR3–SERPIN A1 in patients with other acute coronary
syndromesshouldbeinvestigated(e.g.inthosewithnon-
STelevationAMIorchestpain).Largerstudiesmayneed
to be performed to conﬁrm the utility of PR3–SERPIN
A1 in reclassiﬁcation analyses.
Conclusion
This is the ﬁrst report showing a potential role for
the serine protease PR3 in determining mortality and
incidence of heart failure following AMI, independent of
established conventional risk factors and also the newly
introduced biomarker NT-proBNP. The involvement of
PR3 in pathophysiology of Wegener’s granulomatosis
may extend to more common presentations of vascular
disease. A multimarker approach with clinical risk scores
and either or both of PR3–SERPIN A1 and NT-proBNP
may be useful for risk stratiﬁcation in AMI patients,
both markers providing complementary independent
prediction, and the identiﬁcation of such high risk
patients may facilitate their subsequent management.
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